Ritlecitinib
also Litfulo, PF-06651600
- Approved (Litfulo) · oral · Pfizer · FDA approved · EMA approved · Severe alopecia areata only
JAK3/TEC kinase inhibitor approved for severe alopecia areata (not pattern hair loss), sold as Litfulo
Ritlecitinib, sold under the brand name Litfulo, is a medication used for the treatment of severe alopecia areata. Ritlecitinib is a kinase inhibitor which inhibits Janus kinase 3 and tyrosine kinase.
Read “Ritlecitinib” on Wikipedia · text from Wikipedia, CC BY-SA 4.0
Information, not medical advice. Talk to a licensed doctor or pharmacist before starting or changing a treatment.
Research 10
- Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers
- Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata
- Beyond Hair Regrowth: Interpreting the Psychosocial Impact of Ritlecitinib in Alopecia Areata
- A Plain Language Summary on Ritlecitinib Treatment for Adults and Adolescents with Alopecia Areata
- Ritlecitinib: First Approval
- Characterizing the relationships between patient‐reported outcomes and clinician assessments of alopecia areata in a phase 2a randomized trial of ritlecitinib and brepocitinib
- Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial
- Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway
- Patient satisfaction with hair regrowth in a study of ritlecitinib: a plain language summary
- Hydrogel forming microneedles loaded with VEGF and Ritlecitinib/polyhydroxyalkanoates nanoparticles for mini-invasive androgenetic alopecia treatment
- When JAK Selectivity Matters: Worsening Urticaria and Recurrent Allergic Rhinitis After Switching From Baricitinib to Ritlecitinib in Alopecia Areata
- Comparative Efficacy of Ritlecitinib, Baricitinib, and Upadacitinib in Adolescents With Severe Alopecia Areata: A Bayesian Network Meta‑Analysis
- Ritlecitinib: A Review in Severe Alopecia Areata
- Real-World Safety of Janus Kinase Inhibitors in Alopecia Areata: A Propensity Score-Matched Cohort Study of a Global Federated Health Network
- Patterns of Clinical Response in Rollover Adolescent Patients with Alopecia Areata Treated with Ritlecitinib in the Ongoing Long-Term, Open-Label, Phase 3 ALLEGRO-LT Study
- Pediatric alopecia areata and JAK inhibitors: Bridging the gap between evidence and practice
- JAK Inhibitors for Alopecia Areata: Approved Therapies, Efficacy, and Unanswered Questions
- Baricitinib versus ritlecitinib for severe alopecia areata: A 24‐week real‐world study
- Alopecia Areata: Current and Emerging Therapies
- Upadacitinib for Severe Alopecia Areata in Adults and Adolescents
Posts 7
- Anyone else taking Litfulo (ritlecitinib) to treat their alopecia?
- LITFULO (ritlecitinib tosylate)
- So we have 20k dollars human like machines available but no new effective treatment for hairloss since finasteride :)
- Most promising cures for baldness as of May 2026
- Any new treatment or hope for hairloss?
- If RU58841 is such an effective anti androgen
- Which 2026 hair‑loss treatments have the strongest evidence so far? (minoxidil/finasteride vs. clascoterone, PP405, Re:You’s NV‑623/624, AMP‑303, RU58841)